[
  {
    "ts": null,
    "headline": "Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma",
    "summary": "First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple myeloma (MM). The trial included p",
    "url": "https://finnhub.io/api/news?id=3078ae3f869636dab0129cf705ff39dbd9fe1529f6a750c7c49a499119aa46f1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747947600,
      "headline": "Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma",
      "id": 134658885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "First results to be presented in two ASCO oral presentations Data in both combinations demonstrate high response rates TARRYTOWN, N.Y., May 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced initial results from two cohorts of the Phase 1b LINKER-MM2 trial evaluating linvoseltamab in combination with two different proteasome inhibitors (PI) – carfilzomib or bortezomib – in patients with relapsed/refractory (R/R) multiple myeloma (MM). The trial included p",
      "url": "https://finnhub.io/api/news?id=3078ae3f869636dab0129cf705ff39dbd9fe1529f6a750c7c49a499119aa46f1"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=7a7fcb170341ab57d49034c4ae3daf605760f7a2b6b89934d2aff1e08d5840f3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747932180,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "id": 134668450,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=7a7fcb170341ab57d49034c4ae3daf605760f7a2b6b89934d2aff1e08d5840f3"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Made A “Very Smart Deal,” Says Jim Cramer",
    "summary": "We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on the Street, […]",
    "url": "https://finnhub.io/api/news?id=04beeaffb8215d3e46504ed2e1c4e8d65b0ea73e63af8d6787a5fd60b0949802",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1747923485,
      "headline": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Made A “Very Smart Deal,” Says Jim Cramer",
      "id": 134658886,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "We recently published a list of Jim Cramer Reveals “Quiet” Stock That Goes Up In This List Of 12 Stocks. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on the Street, […]",
      "url": "https://finnhub.io/api/news?id=04beeaffb8215d3e46504ed2e1c4e8d65b0ea73e63af8d6787a5fd60b0949802"
    }
  }
]